

## Special Issue

# Brain Tumor: Recent Advances and Challenges

### Message from the Guest Editor

In recent years, we have observed enormous refinements in the field of brain tumors. Molecular-based diagnosis has become a new standard for a variety of brain tumors. Progress in minimally invasive surgeries, typified by neuroendoscopic surgery, is now key for enhanced recovery and patient wellness. Targeted therapies and immune checkpoint inhibitors are shedding light on many challenging tumors. Various radiotherapeutic modalities have become available, fortifying multidisciplinary treatments. These revolutionary advancements have undoubtedly been driven by progress in the basic sciences. In this Special Issue, we welcome original articles and comprehensive reviews focusing on high-quality basic and clinical research on brain tumors, particularly those focusing on recent advances and challenges in this field.

---

### Guest Editor

Dr. Hirotaka Hasegawa

Faculty of Medicine University Hospital, Department of Neurosurgery,  
The University of Tokyo, Tokyo, Japan

---

### Deadline for manuscript submissions

closed (15 December 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/si/162428](https://mdpi.com/si/162428)

*Cancers*

MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)